» Articles » PMID: 29909039

Integrin α and EGFR Signaling Converge at Mechanosensitive Calpain 2

Overview
Journal Biomaterials
Date 2018 Jun 18
PMID 29909039
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cells sense and respond to mechanical cues from the extracellular matrix (ECM) via integrins. ECM stiffness is known to enhance integrin clustering and response to epidermal growth factor (EGF), but we lack information on when or if these mechanosensitive growth factor receptors and integrins converge intracellularly. Towards closing this knowledge gap, we combined a biomaterial platform with transcriptomics, molecular biology, and functional assays to link integrin-mediated mechanosensing and epidermal growth factor receptor (EGFR) signaling. We found that high integrin α expression controlled breast cancer cell adhesion and motility on soft, laminin-coated substrates, and this mimicked the response of cells to EGF stimulation. The mechanisms that drove both mechanosensitive cell adhesion and motility converged on calpain 2, an intracellular protease important for talin cleavage and focal adhesion turnover. EGF stimulation enhanced adhesion and motility on soft substrates, but required integrin α and calpain 2 signaling. In sum, we identified a new role for integrin α mechanosensing in breast cancer, wherein cell adhesion to laminin on soft substrates mimicked EGF stimulation. We identified calpain 2, downstream of both integrin α engagement and EGFR phosphorylation, as a common intracellular signaling node, and implicate integrin α and calpain 2 as potential targets to inhibit the migration of cancer cells in stiff tumor environments.

Citing Articles

Interstitial Fluid Shear Stress Induces the Synthetic Phenotype Switching of VSMCs to Release Pro-calcified Extracellular Vesicles via EGFR-MAPK-KLF5 Pathway.

Gao W, Gu K, Ma L, Yang F, Deng L, Zhang Y Int J Biol Sci. 2024; 20(7):2727-2747.

PMID: 38725857 PMC: 11077359. DOI: 10.7150/ijbs.90725.


Piezo1 activates noncanonical EGFR endocytosis and signaling.

Pardo-Pastor C, Rosenblatt J Sci Adv. 2023; 9(39):eadi1328.

PMID: 37756411 PMC: 10530101. DOI: 10.1126/sciadv.adi1328.


Calpain-mediated Mechanoptosis in Breast Adenocarcinoma.

Metaxas G, Spyropoulou D, Mastronikoli S, Tsiambas E, Falidas E, Marinopoulos S Cancer Diagn Progn. 2023; 3(3):297-301.

PMID: 37168957 PMC: 10165377. DOI: 10.21873/cdp.10215.


Force- and cell state-dependent recruitment of Piezo1 drives focal adhesion dynamics and calcium entry.

Yao M, Tijore A, Cheng D, Li J, Hariharan A, Martinac B Sci Adv. 2022; 8(45):eabo1461.

PMID: 36351022 PMC: 9645726. DOI: 10.1126/sciadv.abo1461.


Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex.

Zheng G, Bouamar H, Cserhati M, Zeballos C, Mehta I, Zare H Int J Cancer. 2022; 151(6):930-943.

PMID: 35657344 PMC: 9329238. DOI: 10.1002/ijc.34146.


References
1.
Saxena M, Liu S, Yang B, Hajal C, Changede R, Hu J . EGFR and HER2 activate rigidity sensing only on rigid matrices. Nat Mater. 2017; 16(7):775-781. PMC: 5920513. DOI: 10.1038/nmat4893. View

2.
Kim B, Gao M, Choi Y, Kang S, Park H, Kang K . Invasive breast cancer induces laminin-332 upregulation and integrin β4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling. Breast Cancer Res. 2012; 14(3):R88. PMC: 3446351. DOI: 10.1186/bcr3203. View

3.
Cox T, Erler J . Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech. 2011; 4(2):165-78. PMC: 3046088. DOI: 10.1242/dmm.004077. View

4.
Hwang J, Byun M, Kim A, Kim K, Cho H, Lee Y . Extracellular Matrix Stiffness Regulates Osteogenic Differentiation through MAPK Activation. PLoS One. 2015; 10(8):e0135519. PMC: 4532446. DOI: 10.1371/journal.pone.0135519. View

5.
Zhang X, Fournier M, Ware J, Bissell M, Yacoub A, Zehner Z . Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol Cancer Ther. 2009; 8(3):499-508. PMC: 2703491. DOI: 10.1158/1535-7163.MCT-08-0544. View